Timur Gusov, MD
Endocrinology, Diabetes & Metabolism · Milwaukee, WINPI 1144633868
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,066 of the $4,968 with a category attached, or 81.8%. It is spread thinly across 36 manufacturers, the largest accounting for just 23.9% — the pattern of someone who eats at a lot of different presentations.
Across 182 payments — averaging $27.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$1K
- Amgen$389
- Novo Nordisk$388
- AbbVie$354
- Lilly USA, LLC$330
- Sanofi-aventis U.S. LLC$294
- plus $2K from 30 others
What the payments were for
- Travel & lodging$88618%
- Food & beverage$4,06682%
- Entertainment$160%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 9 | $1,187 |
| Amgen | 20 | $389 |
| Novo Nordisk | 20 | $388 |
| AbbVie | 17 | $354 |
| Lilly USA, LLC | 14 | $330 |
| Sanofi-aventis U.S. LLC | 9 | $294 |
| Abbott | 11 | $261 |
| Radius Health, Inc. | 7 | $214 |
| Dexcom, Inc. | 4 | $144 |
| Boehringer Ingelheim | 7 | $136 |
| AstraZeneca(2 entities) | 6 | $135 |
| Nevro Corp. | 6 | $115 |
| Merck | 5 | $111 |
| Ascensia Diabetes Care US Inc. | 6 | $109 |
| Cequr Corporation | 2 | $91 |
| Bayer | 4 | $63 |
| Recordati_rare_diseases_inc. | 3 | $62 |
| Aimmune Therapeutics, Inc. | 3 | $61 |
| Insulet Corporation | 2 | $51 |
| Corcept Therapeutics | 2 | $49 |
| Averitas Pharma Inc. | 2 | $49 |
| Paratek Pharmaceuticals, Inc. | 3 | $43 |
| Melinta Therapeutics, LLC | 2 | $36 |
| Tandem Diabetes Care, Inc. | 3 | $35 |
| Xeris Pharmaceuticals, Inc. | 2 | $35 |
| Kyowa Kirin, Inc. | 2 | $34 |
| Organogenesis Inc. | 2 | $27 |
| Johnson & Johnson | 1 | $23 |
| Shionogi Inc | 1 | $21 |
| Viiv Healthcare Company | 1 | $21 |
| Chiesi USA, Inc. | 1 | $20 |
| Ultragenyx Pharmaceutical Inc. | 1 | $18 |
| Halozyme Inc | 1 | $18 |
| Optos, Inc. | 1 | $16 |
| Rhythm Pharmaceuticals, Inc. | 1 | $14 |
| Amneal Pharmaceuticals LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MINIMED 780G$313
- FREESTYLE LIBRE 3$128
- SOLIQUA 100/33$103
How this compares
$4,968 in reported general payments places this provider in the 80th percentile of 127 endocrinology, diabetes & metabolism providers in Wisconsin.
See all endocrinology, diabetes & metabolism providers in Wisconsin →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 200 | $243,702 |
| MounjaroTirzepatide | 118 | $144,653 |
| MycapssaOctreotide Acetate | 11 | $72,934 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 71 | $71,027 |
| JardianceEmpagliflozin | 74 | $69,462 |
| Humalog Kwikpen U-200Insulin Lispro | 34 | $42,914 |
| Tresiba Flextouch U-100Insulin Degludec | 27 | $28,960 |
| TrulicityDulaglutide | 25 | $26,627 |
| FarxigaDapagliflozin Propanediol | 21 | $25,551 |
| JanuviaSitagliptin Phosphate | 19 | $23,022 |
| Tresiba Flextouch U-200Insulin Degludec | 13 | $20,728 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 14 | $19,916 |
| Insulin Lispro Kwikpen U-100Insulin Lispro | 54 | $18,273 |
| RybelsusSemaglutide | 12 | $11,656 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 23 | $11,421 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $388 | $255,358212 claims |
| Lilly USA, LLCMounjaro, Trulicity, Insulin Lispro | $330 | $172,864157 claims |
| Chiesi USA, Inc.Mycapssa | $20 | $72,93411 claims |
| Boehringer IngelheimJardiance | $136 | $69,46274 claims |
| AstraZenecaFarxiga | $135 | $25,55121 claims |
| MerckJanuvia | $111 | $23,02219 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $13 | $1,556160 claims |
| AbbVieSynthroid | $354 | $1,52820 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 127 endocrinology, diabetes & metabolism providers in Wisconsin.
Other endocrinology, diabetes & metabolism in Milwaukee
- Denise Teves QuallerMilwaukee$56K
- Elaine DrobnyMilwaukee$29K
- Adriana IoachimescuMilwaukee$26K
- Catherine ZhangMilwaukee$16K
- Antoni GofronMilwaukee$5K
- Anil ChandelMilwaukee$3K
- Michael VossMilwaukee$2K
- Olena KlindukhovaMilwaukee$1K
- Usonwanne IbekweMilwaukee$1K
- Veitla RaoMilwaukee$658
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.